NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RLAY

Relay Therapeutics Inc

Jul 02 • 02:05PM ET

3.58

Dollar change +0.06
Percentage change 1.56	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX NTLA BEAM CRSP BLUE EDIT BMRN ADPT SGMO IONQ

| Held by: VTI IWM XBI VXF VB IWN VBK IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.23	Insider Own	24.60%	Shs Outstand	170.48M	Perf Week	9.66%
Market Cap	612.92M	Forward P/E	-	EPS next Y	-1.84	Insider Trans	-2.44%	Shs Float	129.27M	Perf Month	12.42%
Enterprise Value	-50.28M	PEG	-	EPS next Q	-0.49	Inst Own	83.69%	Short Float	17.42%	Perf Quarter	44.74%
Income	-333.39M	P/S	79.81	EPS this Y	21.05%	Inst Trans	14.73%	Short Ratio	10.32	Perf Half Y	-18.00%
Sales	7.68M	P/B	0.85	EPS next Y	1.47%	ROA	-40.64%	Short Interest	22.52M	Perf YTD	-13.23%
Book/sh	4.23	P/C	0.86	EPS next 5Y	10.83%	ROE	-45.46%	52W High	10.72 -66.65%	Perf Year	-45.17%
Cash/sh	4.14	P/FCF	-	EPS past 3/5Y	14.82% -23.05%	ROIC	-43.73%	52W Low	1.77 101.41%	Perf 3Y	-80.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	48.94% -	Gross Margin	31.28%	Volatility	6.69% 7.56%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-6.55	EPS Y/Y TTM	15.41%	Oper. Margin	-4927.05%	ATR (14)	0.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.96	Sales Y/Y TTM	-78.26%	Profit Margin	-4341.53%	RSI (14)	61.73	Recom	1.42
Dividend Gr. 3/5Y	- -	Current Ratio	19.96	EPS Q/Q	26.78%	SMA20	7.45%	Beta	1.62	Target Price	13.90
Payout	-	Debt/Eq	0.07	Sales Q/Q	-23.26%	SMA50	13.22%	Rel Volume	0.58	Prev Close	3.52
Employees	261	LT Debt/Eq	0.06	Earnings	May 05 AMC	SMA200	-17.32%	Avg Volume	2.18M	Price	3.58
IPO	Jul 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.99% 53599.30%	Trades		Volume	910,528	Change	1.56%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-25	Initiated	Wells Fargo	Equal Weight	$4
Sep-10-24	Upgrade	Jefferies	Hold → Buy	$10.60 → $16
Sep-10-24	Resumed	Goldman	Buy	$20
Sep-10-24	Downgrade	Oppenheimer	Outperform → Perform
May-10-24	Upgrade	Barclays	Equal Weight → Overweight	$15
Apr-20-23	Upgrade	Jefferies	Underperform → Hold	$12.50
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy	$29
Apr-13-23	Initiated	Raymond James	Outperform	$29
Feb-03-23	Initiated	Oppenheimer	Outperform	$33
Sep-30-22	Initiated	Barclays	Equal Weight	$23
Sep-02-22	Initiated	Stifel	Buy	$40
Jun-06-22	Initiated	Jefferies	Underperform	$13
Feb-01-22	Initiated	Berenberg	Buy	$45
Jul-21-21	Initiated	BofA Securities	Buy	$50
Dec-15-20	Reiterated	H.C. Wainwright	Buy	$54 → $57
Dec-08-20	Initiated	JMP Securities	Mkt Outperform	$66
Nov-05-20	Initiated	H.C. Wainwright	Buy	$54
Aug-10-20	Initiated	JP Morgan	Neutral	$36
Aug-10-20	Initiated	Guggenheim	Buy	$48
Aug-10-20	Initiated	Goldman	Buy	$64

Show Previous Ratings

Today 10:28AM	Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? (Zacks)
Jun-24-25 03:51PM	BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT (Insider Monkey)
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -5.06%
Jun-11-25 04:05PM	Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors (GlobeNewswire)
Jun-09-25 11:37AM	Relay Therapeutics, Inc. (RLAY): A Bull Case Theory (Insider Monkey)
07:00AM	Loading…
Jun-02-25 07:00AM	Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 (GlobeNewswire) +6.00%
May-29-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June (GlobeNewswire)
May-27-25 09:45AM	Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders (PR Newswire)
May-23-25 12:00PM	What Makes Relay Therapeutics (RLAY) a New Buy Stock (Zacks)
May-13-25 08:49AM	Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now (Insider Monkey) -9.00%
May-08-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-07-25 06:58PM	Relay Therapeutics, Inc. (RLAY): A Bull Case Theory (Insider Monkey) -6.35%
May-05-25 04:05PM	Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire) -5.12%
Apr-28-25 04:05PM	Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025 (GlobeNewswire)
Apr-20-25 06:19AM	Relay Therapeutics (RLAY): The Most Promising Penny Stock According to Analysts (Insider Monkey)
10:03AM	Loading…
Apr-16-25 10:03AM	Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -5.43%
09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
Apr-12-25 09:28AM	Relay Therapeutics: Trying To Find That Right Price (Seeking Alpha)
Apr-09-25 09:44AM	Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple (Insider Monkey) +15.00%
05:00AM	Barbara Weber, M.D., Elected to ITM Supervisory Board (GlobeNewswire)
Mar-31-25 09:56AM	Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines! (Insider Monkey)
Mar-05-25 09:35AM	Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY) (Zacks) +6.27%
Feb-26-25 04:05PM	Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates (GlobeNewswire) -13.33%
Feb-25-25 10:48AM	What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnings (GuruFocus.com) -5.15%
Feb-24-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Feb-19-25 04:05PM	Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 (GlobeNewswire) +6.12%
Jan-24-25 12:09PM	Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays $17 Price Target (Insider Monkey)
Jan-07-25 04:05PM	Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:57PM	Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now? (Insider Monkey)
Dec-20-24 12:00PM	Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade (Zacks)
05:49PM	Loading…
Dec-13-24 05:49PM	Relay Therapeutics, Inc. (RLAY): A Bull Case Theory (Insider Monkey)
Dec-11-24 06:00AM	Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival (GlobeNewswire) +12.42%
Dec-09-24 04:05PM	Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -5.74%
Dec-06-24 09:35AM	After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY) (Zacks) +7.71%
Dec-05-24 06:51AM	Relay Therapeutics price target lowered to $18 from $19 at Leerink (TipRanks)
Dec-04-24 04:36PM	Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Dec-03-24 08:01AM	Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors (GlobeNewswire) -6.00%
08:00AM	Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors (GlobeNewswire)
Nov-20-24 09:35AM	Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround (Zacks)
Nov-19-24 09:35AM	Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround (Zacks)
Nov-07-24 04:05PM	Relay Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 04:05PM	Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire) +5.04%
Oct-30-24 04:05PM	Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 (GlobeNewswire)
Sep-17-24 08:24AM	Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength? (Zacks) -6.29%
Sep-11-24 06:46PM	Why Relay Therapeutics Plummeted by Nearly 14% Today (Motley Fool) -13.83%
Sep-10-24 08:21PM	Relay Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -5.36%
Sep-09-24 04:34PM	Relay Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +52.40%
11:30AM	Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients (Benzinga)
08:07AM	Relay breast cancer drug shows potential in early trial (BioPharma Dive)
06:55AM	Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival (GlobeNewswire)
Sep-06-24 04:05PM	Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024 (GlobeNewswire)
Aug-06-24 04:05PM	Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire) -7.93%
Jul-30-24 04:05PM	Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024 (GlobeNewswire)
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jun-06-24 07:00AM	Relay Therapeutics Discloses Three New Programs at New Program & Platform Event (GlobeNewswire)
Jun-05-24 04:05PM	Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608 (GlobeNewswire)
May-21-24 04:05PM	Relay Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.50%
May-13-24 08:30AM	Relay Therapeutics to Host New Program and Platform Event on June 6, 2024 (GlobeNewswire)
May-10-24 10:01AM	Barclays Upgrades Relay Therapeutics to Overweight From Equalweight With $15 Price Target (MT Newswires)
May-06-24 08:57AM	Oppenheimer Adjusts Relay Therapeutics Price Target to $25 From $33, Maintains Outperform Rating (MT Newswires)
May-02-24 09:55PM	RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +6.31%
05:55PM	Relay Therapeutics Outperforms Revenue Expectations in Q1 2024 (GuruFocus.com)
05:40PM	Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Apr-25-24 04:05PM	Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024 (GlobeNewswire)
Apr-11-24 04:05PM	Relay Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Mar-15-24 12:39PM	3 Precision Medicine Stocks That Could Benefit From the Industrys Rise (InvestorPlace)
Mar-13-24 09:55AM	Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect? (Zacks)
Feb-26-24 04:05PM	Relay Therapeutics to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
09:55AM	Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High? (Zacks)
Feb-22-24 04:40PM	Relay Therapeutics Inc (RLAY) Reports Full Year 2023 Financial Results and Corporate Highlights (GuruFocus.com) -5.39%
04:05PM	Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-15-24 04:05PM	Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024 (GlobeNewswire) +7.89%
10:00AM	Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
03:29AM	Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last? (Zacks)
Feb-01-24 04:05PM	Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-18-24 05:37AM	Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential (TipRanks)
Jan-08-24 07:00AM	Relay Therapeutics Announces $30 Million Private Placement Financing (GlobeNewswire)
Jan-02-24 04:05PM	Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.67%
Nov-30-23 09:55AM	Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 189.21%: Read This Before Placing a Bet (Zacks)
Nov-14-23 09:55AM	Wall Street Analysts See a 202.33% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High? (Zacks) +7.13%
Nov-07-23 04:05PM	Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference (GlobeNewswire)
Nov-02-23 06:21PM	Relay Therapeutics Inc (RLAY) Reports Q3 2023 Financial Results: Revenue Surges to $25.2 Million (GuruFocus.com) +8.35%
04:05PM	Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-31-23 12:00PM	Top 12 Medical AI Companies (Insider Monkey) +5.94%
Oct-26-23 04:05PM	Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023 (GlobeNewswire) +5.32%
10:02AM	Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-12-23 04:05PM	Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors (GlobeNewswire) -11.02%
Sep-18-23 04:05PM	Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Aug-31-23 10:16PM	12 Best High Risk High Reward Stocks To Buy Now (Insider Monkey) +7.93%
Aug-08-23 06:05PM	Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +7.71%
04:02PM	Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-01-23 04:05PM	Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023 (GlobeNewswire) -5.48%
May-25-23 05:01PM	Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008 (GlobeNewswire)
May-24-23 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-18-23 08:16AM	Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-04-23 07:25PM	Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Apr-27-23 04:05PM	Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rahmer Peter	See remarks	Apr 30 '25	Sale	3.00	10,739	32,217	390,081	Apr 30 08:25 PM
Rahmer Peter	See remarks	Apr 28 '25	Sale	3.17	1,364	4,324	400,820	Apr 30 08:25 PM
Catinazzo Thomas	Chief Financial Officer	Apr 30 '25	Sale	3.00	12,943	38,829	355,376	Apr 30 08:24 PM
Catinazzo Thomas	Chief Financial Officer	Apr 29 '25	Sale	3.23	3,558	11,492	368,319	Apr 30 08:24 PM
Catinazzo Thomas	Chief Financial Officer	Apr 28 '25	Sale	3.17	2,690	8,527	371,877	Apr 30 08:24 PM
Bergstrom Donald A	President, R&D	Apr 30 '25	Sale	3.00	27,472	82,416	583,490	Apr 30 08:24 PM
Bergstrom Donald A	President, R&D	Apr 28 '25	Sale	3.17	4,090	12,965	610,962	Apr 30 08:24 PM
Adams Brian	Chief Legal Officer	Apr 30 '25	Sale	3.00	12,943	38,829	391,385	Apr 30 08:23 PM
Adams Brian	Chief Legal Officer	Apr 28 '25	Sale	3.17	1,644	5,211	404,328	Apr 30 08:23 PM
THOMAS J CATINAZZO	Officer	Apr 29 '25	Proposed Sale	3.23	3,558	11,492		Apr 29 04:01 PM
THOMAS J CATINAZZO	Officer	Apr 28 '25	Proposed Sale	3.17	981	3,110		Apr 28 04:02 PM
Patel Sanjiv	President and CEO	Apr 23 '25	Sale	2.97	61,422	182,423	821,667	Apr 24 04:03 PM
Bergstrom Donald A	President, R&D	Mar 27 '25	Sale	2.84	986	2,800	615,052	Mar 31 04:19 PM
Rahmer Peter	See remarks	Mar 27 '25	Sale	2.84	247	701	402,184	Mar 31 04:15 PM
Catinazzo Thomas	Chief Financial Officer	Mar 27 '25	Sale	2.84	4,864	13,814	374,567	Mar 31 04:13 PM
Adams Brian	Chief Legal Officer	Mar 27 '25	Sale	2.84	298	846	405,972	Mar 31 04:12 PM
THOMAS J CATINAZZO	Officer	Mar 27 '25	Proposed Sale	2.84	4,566	12,967		Mar 27 04:03 PM
Patel Sanjiv	President and CEO	Feb 11 '25	Sale	3.85	140,182	539,701	625,948	Feb 13 08:56 PM
Patel Sanjiv	President and CEO	Feb 13 '25	Sale	3.70	75,324	278,699	883,089	Feb 13 08:56 PM
Rahmer Peter	See remarks	Jan 29 '25	Sale	4.55	26,541	120,762	419,681	Jan 30 09:16 PM
Rahmer Peter	See remarks	Jan 30 '25	Sale	4.42	17,250	76,245	402,431	Jan 30 09:16 PM
Rahmer Peter	See remarks	Jan 28 '25	Sale	4.63	1,673	7,746	307,081	Jan 30 09:16 PM
Catinazzo Thomas	Chief Financial Officer	Jan 28 '25	Sale	4.63	36,036	166,847	263,190	Jan 30 09:10 PM
Catinazzo Thomas	Chief Financial Officer	Jan 30 '25	Sale	4.42	20,791	91,896	379,431	Jan 30 09:10 PM
Catinazzo Thomas	Chief Financial Officer	Jan 29 '25	Sale	4.55	2,109	9,596	400,222	Jan 30 09:10 PM
Bergstrom Donald A	President, R&D	Jan 29 '25	Sale	4.55	46,407	211,152	646,861	Jan 30 09:06 PM
Bergstrom Donald A	President, R&D	Jan 30 '25	Sale	4.42	30,823	136,238	616,038	Jan 30 09:06 PM
Bergstrom Donald A	President, R&D	Jan 28 '25	Sale	4.63	3,220	14,909	516,868	Jan 30 09:06 PM
Adams Brian	Chief Legal Officer	Jan 28 '25	Sale	4.63	33,688	155,975	287,920	Jan 30 09:02 PM
Adams Brian	Chief Legal Officer	Jan 30 '25	Sale	4.42	20,791	91,896	406,270	Jan 30 09:02 PM
THOMAS J CATINAZZO	Officer	Jan 29 '25	Proposed Sale	4.55	2,109	9,596		Jan 29 04:03 PM
THOMAS J CATINAZZO	Officer	Jan 28 '25	Proposed Sale	4.63	2,283	10,570		Jan 28 04:48 PM
Patel Sanjiv	President and CEO	Jan 22 '25	Sale	4.80	125,000	600,000	324,548	Jan 23 07:01 PM
Patel Sanjiv	President and CEO	Jan 23 '25	Sale	4.78	125,000	597,500	199,548	Jan 23 07:01 PM
Patel Sanjiv	President and CEO	Jan 21 '25	Sale	4.52	125,000	565,000	449,548	Jan 23 07:01 PM
THE PATEL FAMILY IRREVOCABLE U	Officer	Jan 23 '25	Proposed Sale	4.78	125,000	597,162		Jan 23 04:03 PM
THE PATEL FAMILY IRREVOCABLE U	Officer	Jan 22 '25	Proposed Sale	4.80	125,000	599,575		Jan 22 04:04 PM
THE PATEL FAMILY IRREVOCABLE U	Officer	Jan 21 '25	Proposed Sale	4.52	125,000	565,312		Jan 21 04:08 PM
Rahmer Peter	See remarks	Jan 03 '25	Sale	4.30	32,177	138,361	325,330	Jan 06 08:35 PM
Rahmer Peter	See remarks	Jan 02 '25	Sale	4.15	32,156	133,447	357,507	Jan 06 08:35 PM
Rahmer Peter	See remarks	Jan 06 '25	Sale	4.45	16,576	73,763	308,754	Jan 06 08:35 PM
PETER J RAHMER	Officer	Jan 06 '25	Proposed Sale	4.45	16,576	73,727		Jan 06 04:05 PM
PETER J RAHMER	Officer	Jan 03 '25	Proposed Sale	4.30	32,177	138,490		Jan 03 04:11 PM
Adams Brian	Chief Legal Officer	Dec 27 '24	Sale	4.38	299	1,310	321,608	Dec 31 04:05 PM
Bergstrom Donald A	President, R&D	Dec 27 '24	Sale	4.38	657	2,878	520,088	Dec 31 04:05 PM
Catinazzo Thomas	Chief Financial Officer	Dec 27 '24	Sale	4.42	4,865	21,491	299,226	Dec 31 04:05 PM
Rahmer Peter	See remarks	Dec 27 '24	Sale	4.38	400	1,752	389,663	Dec 31 04:05 PM
THOMAS J CATINAZZO	Officer	Dec 27 '24	Proposed Sale	4.42	4,566	20,189		Dec 27 04:01 PM
Patel Sanjiv	President and CEO	Dec 16 '24	Sale	5.00	100,000	500,000	574,548	Dec 18 04:51 PM
THE PATEL FAMILY IRREVOCABLE U	Officer	Dec 16 '24	Proposed Sale	5.00	100,000	500,000		Dec 16 04:18 PM
Rahmer Peter	See remarks	Oct 28 '24	Sale	6.06	1,621	9,823	390,063	Oct 30 04:09 PM
Catinazzo Thomas	Chief Financial Officer	Oct 28 '24	Sale	6.06	6,802	41,220	306,391	Oct 30 04:09 PM
Catinazzo Thomas	Chief Financial Officer	Oct 29 '24	Sale	5.95	2,300	13,685	304,091	Oct 30 04:09 PM
Bergstrom Donald A	President, R&D	Oct 28 '24	Sale	6.06	2,688	16,289	520,745	Oct 30 04:08 PM
Adams Brian	Chief Legal Officer	Oct 28 '24	Sale	6.06	1,632	9,890	321,907	Oct 30 04:07 PM
THOMAS J CATINAZZO	Officer	Oct 29 '24	Proposed Sale	5.95	2,300	13,685		Oct 29 04:04 PM
THOMAS J CATINAZZO	Officer	Oct 28 '24	Proposed Sale	6.06	5,105	30,936		Oct 28 04:05 PM
Rahmer Peter	See remarks	Sep 27 '24	Sale	7.51	245	1,840	391,684	Oct 01 04:07 PM
Catinazzo Thomas	Chief Financial Officer	Sep 27 '24	Sale	7.46	6,457	48,184	313,193	Oct 01 04:07 PM
Bergstrom Donald A	President, R&D	Sep 27 '24	Sale	7.51	648	4,866	523,433	Oct 01 04:07 PM
Adams Brian	Chief Legal Officer	Sep 27 '24	Sale	7.51	295	2,215	323,539	Oct 01 04:06 PM
THOMAS J CATINAZZO	Officer	Sep 27 '24	Proposed Sale	7.46	6,162	45,977		Sep 27 04:27 PM
Catinazzo Thomas	Chief Financial Officer	Jul 29 '24	Sale	8.56	10,780	92,316	319,650	Jul 31 06:43 PM
Rahmer Peter	See remarks	Jul 30 '24	Sale	8.28	15,128	125,260	405,637	Jul 31 06:43 PM
Rahmer Peter	See remarks	Jul 29 '24	Sale	8.54	13,523	115,543	420,765	Jul 31 06:43 PM
Rahmer Peter	See remarks	Jul 31 '24	Sale	8.19	13,708	112,269	391,929	Jul 31 06:43 PM
Bergstrom Donald A	President, R&D	Jul 29 '24	Sale	8.85	2,698	23,877	524,081	Jul 31 06:42 PM
Adams Brian	Chief Legal Officer	Jul 29 '24	Sale	8.85	1,638	14,496	323,834	Jul 31 06:42 PM
PETER J RAHMER	Officer	Jul 31 '24	Proposed Sale	8.19	13,708	112,245		Jul 31 04:06 PM
PETER J RAHMER	Officer	Jul 30 '24	Proposed Sale	8.28	15,128	125,290		Jul 30 04:19 PM
Patel Sanjiv	President and CEO	Jul 25 '24	Option Exercise	5.04	50,000	252,000	816,130	Jul 29 06:37 PM
Patel Sanjiv	President and CEO	Jul 26 '24	Option Exercise	5.04	36,706	184,998	802,836	Jul 29 06:37 PM
Patel Sanjiv	President and CEO	Jul 25 '24	Sale	9.16	50,000	458,000	766,130	Jul 29 06:37 PM
Patel Sanjiv	President and CEO	Jul 26 '24	Sale	9.07	36,706	332,923	766,130	Jul 29 06:37 PM
THOMAS J CATINAZZO	Officer	Jul 29 '24	Proposed Sale	8.51	9,078	77,243		Jul 29 04:29 PM
PETER J RAHMER	Officer	Jul 29 '24	Proposed Sale	8.51	12,164	103,488		Jul 29 04:24 PM
SANJIV PATEL	Officer	Jul 26 '24	Proposed Sale	9.07	36,706	332,769		Jul 26 04:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RLAY

Relay Therapeutics Inc

Upgrade your FINVIZ experience